
Opinion|Videos|July 19, 2024
The Role of MRD Testing in Guiding Treatment in R/R MM: ASCO 2024 Updates from PERSEUS
Following ASCO 2024, Samer Al'Hadidi, MD, discusses recent updates from the PERSEUS trial evaluating the role of testing for minimal residual disease (MRD) in guiding treatment for relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Please comment on the recent updates from the analysis of minimal residual disease (MRD) in the PERSEUS trial.
Advertisement
Related to this article

Hematologic specialists discussed where ciltacabtagene autoleucel fits in the treatment paradigm at first relapse and beyond in multiple myeloma.

C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.

Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.

Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“We should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Aglatimagene Combo Shows Sustained Immune Remodeling in Prostate Cancer
2
What Does TALAPRO-3 Mean for Frontline Treatment of HRR-Altered mHSPC?
3
Referral Barriers to Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma
4
SBRT Matches Chemoradiation, Preserves QOL Before Pancreatic Surgery
5


